Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059)

A Double-Blind, Multicenter, Placebo- and Active-Controlled Acute and Extension Study of MK0869 in the Treatment of Patients With Major Depressive Disorder With Melancholic Features

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00035009

Enrollment

468

Registered

2002-05-03

Start date

2001-09-20

Completion date

2004-03-24

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Brief summary

A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression

Detailed description

The duration of treatment is 8 weeks.

Interventions

DRUGMK0869, aprepitant

DRUGComparator: paroxetine HCL

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Major Depressive Disorder

Design outcomes

Primary

Measure	Time frame
Change from baseline in HAMD-17 total score at week 8. Mk-0869 will be generally well tolerated	—

Secondary

Measure	Time frame
Actual CGI-I score at week 8, improving social disability by change from baseline in Sheehan Disability Score at Week 8, change from baseline in the HAMA score at week 8, change from baseline in depressed mood of the HAMD-17 at week 8	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026